Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ayurcann HoldingsAYURF 3-Year EBITDA Growth Rate is 28.90% as of Sep. 2025, which is 54% above its 10-year median of 18.80. The stock has 2 warning signs investors should review. Among 808 Drug Manufacturers companies, Ayurcann Holdings ranks better than 77.23% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 28.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ayurcann Holdings was 46.50% per year. The lowest was -72.00% per year. And the median was 18.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Ayurcann Holdings 3-Year EBITDA Growth Rate Related Terms
AYURF vs KAYS, PNXP, CBSTQ: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ayurcann Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ayurcann Holdings 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ayurcann Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Ayurcann Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 28.90% mean?
Ayurcann Holdings (AYURF) has a 3-Year EBITDA Growth Rate of 28.90% as of Sep. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ayurcann Holdings and its competitors. This is 54% above median its historical median of 18.80. According to the industry distribution chart, Ayurcann Holdings ranks #184 out of 808 companies in the Drug Manufacturers industry, placing it in the top 22.8%.
Is Ayurcann Holdings' 3-Year EBITDA Growth Rate too high?
Ayurcann Holdings' current 3-Year EBITDA Growth Rate of 28.90% is 54% above median its 10-year median of 18.80. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Ayurcann Holdings' value of 28.90% is 224.7% above this industry median. Based on the distribution chart, Ayurcann Holdings ranks #184 out of 808 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Ayurcann Holdings' 3-Year EBITDA Growth Rate compare to KAYS and PNXP?
According to the Drug Manufacturers industry distribution chart, Ayurcann Holdings ranks #184 out of 808 companies for 3-Year EBITDA Growth Rate. This places Ayurcann Holdings in the top 23% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Ayurcann Holdings' value of 28.90% is 224.7% above this benchmark. While the company's 10-year median is 18.80 vs. the industry median of 8.90, Ayurcann Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ayurcann Holdings's current 3-Year EBITDA Growth Rate of 28.90% is 224.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ayurcann Holdings and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ayurcann Holdings's current 3-Year EBITDA Growth Rate is 28.90%, which is 54% above median its own 10-year median of 18.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ayurcann Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ayurcann Holdings (AYURF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.04, compared to a current price of $0.00 — trading 99.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 28.90%, which is 54% above median its 10-year median of 18.80 and 224.7% above the Drug Manufacturers industry median of 8.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Ayurcann Holdings (AYURF), the current 3-Year EBITDA Growth Rate is 28.90% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ayurcann Holdings Corp is engaged in providing post-harvest outsourcing solutions to licensed cannabis producers and the manufacture and distribution of cannabis products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AYURF has been successfully added to your 
